EE200200591A - Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks - Google Patents

Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks

Info

Publication number
EE200200591A
EE200200591A EEP200200591A EEP200200591A EE200200591A EE 200200591 A EE200200591 A EE 200200591A EE P200200591 A EEP200200591 A EE P200200591A EE P200200591 A EEP200200591 A EE P200200591A EE 200200591 A EE200200591 A EE 200200591A
Authority
EE
Estonia
Prior art keywords
pyridine
converting
pharmaceutically effective
oxide
oxide derivative
Prior art date
Application number
EEP200200591A
Other languages
English (en)
Inventor
�r�gdi L�szl�
Jegesn� Cs�kai Zita
Gruber Lajos
�tv�s L�szl�
T�th J�zsef
T�m�sk�zi Istv�n
Szak�csn� Schmidt Anik�
Reider Ferencn�
Schneidern� Barlay M�ria
Original Assignee
Biorex Kutat� �s Fejleszto Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutat� �s Fejleszto Rt. filed Critical Biorex Kutat� �s Fejleszto Rt.
Publication of EE200200591A publication Critical patent/EE200200591A/et
Publication of EE05085B1 publication Critical patent/EE05085B1/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
EEP200200591A 2000-04-18 2001-04-17 Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks EE05085B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0001583A HUP0001583A2 (hu) 2000-04-18 2000-04-18 Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
PCT/HU2001/000046 WO2001079174A1 (en) 2000-04-18 2001-04-17 A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds

Publications (2)

Publication Number Publication Date
EE200200591A true EE200200591A (et) 2004-04-15
EE05085B1 EE05085B1 (et) 2008-10-15

Family

ID=90001563

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200591A EE05085B1 (et) 2000-04-18 2001-04-17 Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks

Country Status (32)

Country Link
US (1) US7126002B2 (et)
EP (1) EP1274685B1 (et)
JP (1) JP5066638B2 (et)
KR (1) KR100742482B1 (et)
CN (1) CN1216868C (et)
AT (1) ATE332894T1 (et)
AU (2) AU2001254997B2 (et)
BG (1) BG65889B1 (et)
BR (1) BRPI0110184B8 (et)
CA (1) CA2406266C (et)
CY (1) CY1107473T1 (et)
CZ (1) CZ301576B6 (et)
DE (1) DE60121431T2 (et)
DK (1) DK1274685T3 (et)
EE (1) EE05085B1 (et)
ES (1) ES2267758T3 (et)
HK (1) HK1055741A1 (et)
HR (1) HRP20020825A2 (et)
HU (1) HUP0001583A2 (et)
IL (2) IL152337A0 (et)
MX (1) MXPA02010320A (et)
NO (1) NO323535B1 (et)
NZ (1) NZ522017A (et)
PL (1) PL359826A1 (et)
PT (1) PT1274685E (et)
RS (1) RS51003B (et)
RU (1) RU2281282C2 (et)
SI (1) SI1274685T1 (et)
SK (1) SK287606B6 (et)
UA (1) UA75353C2 (et)
WO (1) WO2001079174A1 (et)
ZA (1) ZA200208460B (et)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
NZ533795A (en) * 2002-01-11 2006-03-31 Biorex Kutato Fejlesztoe Kft Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
CA2728363C (en) 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
AU2011335545A1 (en) 2010-11-30 2013-06-13 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
PT3193840T (pt) 2014-09-15 2021-08-10 Orphazyme Aps Formulação de arimoclomol
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
KR102254140B1 (ko) 2016-04-29 2021-05-24 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
IL299250A (en) 2020-06-24 2023-02-01 Kempharm Denmark As Arimoclomol for the treatment of Gaucher disease
EP4247792A1 (en) * 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
EP4267139A1 (en) 2020-12-24 2023-11-01 Zevra Denmark A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component

Also Published As

Publication number Publication date
IL152337A (en) 2007-10-31
KR100742482B1 (ko) 2007-07-25
DE60121431D1 (de) 2006-08-24
DK1274685T3 (da) 2006-11-06
UA75353C2 (en) 2006-04-17
ES2267758T3 (es) 2007-03-16
CZ301576B6 (cs) 2010-04-21
NO20025015D0 (no) 2002-10-18
YU78302A (sh) 2005-09-19
MXPA02010320A (es) 2004-09-06
AU2001254997B2 (en) 2006-11-23
CZ20023445A3 (cs) 2003-03-12
CN1434800A (zh) 2003-08-06
CY1107473T1 (el) 2012-12-19
RS51003B (sr) 2010-10-31
EE05085B1 (et) 2008-10-15
JP2004501080A (ja) 2004-01-15
JP5066638B2 (ja) 2012-11-07
SK287606B6 (sk) 2011-03-04
SI1274685T1 (sl) 2006-10-31
WO2001079174A8 (en) 2002-12-27
US7126002B2 (en) 2006-10-24
CA2406266C (en) 2010-07-20
BRPI0110184B8 (pt) 2021-05-25
KR20030011309A (ko) 2003-02-07
HUP0001583D0 (en) 2000-06-28
BRPI0110184B1 (pt) 2015-12-29
ZA200208460B (en) 2003-10-20
SK15082002A3 (sk) 2003-05-02
WO2001079174A1 (en) 2001-10-25
HK1055741A1 (en) 2004-01-21
PT1274685E (pt) 2006-09-29
US20040006232A1 (en) 2004-01-08
RU2002130710A (ru) 2004-03-20
NO323535B1 (no) 2007-06-04
PL359826A1 (en) 2004-09-06
EP1274685B1 (en) 2006-07-12
DE60121431T2 (de) 2007-01-18
NZ522017A (en) 2004-06-25
HUP0001583A2 (hu) 2002-11-28
CN1216868C (zh) 2005-08-31
HRP20020825A2 (en) 2004-12-31
ATE332894T1 (de) 2006-08-15
BG107199A (bg) 2003-07-31
BG65889B1 (bg) 2010-04-30
BR0110184A (pt) 2003-06-17
CA2406266A1 (en) 2001-10-25
NO20025015L (no) 2002-12-16
EP1274685A1 (en) 2003-01-15
AU5499701A (en) 2001-10-30
IL152337A0 (en) 2003-05-29
RU2281282C2 (ru) 2006-08-10

Similar Documents

Publication Publication Date Title
CY1107473T1 (el) Ενα παραγωγο pyridine-n-oxide, και διαδικασια για τη μετατροπη του σε αποτελεσματικες φαρμακευτικες συνθεσεις
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
SE0200979D0 (sv) New compounds
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
TW200510375A (en) New compounds
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
SE9901875D0 (sv) Novel compounds
EA200301223A1 (ru) Лекарственные формы окскарбазепина
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BR0311984A (pt) Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
ATE253359T1 (de) Antithrombotische mittel
EA200600866A1 (ru) Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний
ATE286395T1 (de) Antithrombotische mittel
EA200300771A1 (ru) Новая соль бензоилгуанидина
NO996128L (no) Nye pentaerytrittderivater, deres fremstilling og anvendelse så vel som mellomprodukter for deres syntese
NO20014889D0 (no) Fremgangsmåte for fremstilling av medisinske midler
SE9901338D0 (sv) Novel process
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110417